Proceeds from the financing will be used to advance the company's pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

500 Technology Sq. 901
Cambridge, MA 02139
USA

Phone

(617) 603-0070

Website

www.vervetx.com

Email Address

Not Recorded

Overview

Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.

Profile

Social Media

Verve Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Burt Adelman

Chief Executive Officer

Sekar Kathiresan

Chief Scientific Officer

Andrew Bellinger

Co-Founder

Keith Joung

Co-Founder

Kiran Musunuru

Co-Founder

Anthony Philippakis

Co-Founder

Issi Rozen

Co-Founder

Barry Ticho

President

Andrew Ashe

Vice President

Kallanthottathil Rajeev

Vice President

Ellen Rohde

VP - Manufacturing

Christopher Cheng

VP - Marketing

Michele Rozen

VP - R & D

Alexandra Chadwick

VP - Regulatory Affairs

Leslie Stolz

Browse more venture capital transactions:

Prev: 1/20/2021: Aledade venture capital transaction
Next: 1/20/2021: Swimlane venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary